FDA places hold on Kezar Life Sciences' trial for lupus nephritis treatment [Yahoo! Finance]
Kezar Life Sciences, Inc. (KZR)
Last kezar life sciences, inc. earnings: 8/7 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Kezar suspended the dosing and enrolment based on the recommendation from the trial's independent data monitoring committee (IDMC), which reviewed the emerging trial safety data. These findings included an assessment of four Grade five (fatal) serious adverse events (SAEs) that occurred during the trial in patients enrolled in the Philippines and Argentina. The IDMC's review indicated that three of the fatalities shared a pattern of symptoms and occurred close to the time of dosing. Additional non-fatal SAEs also displayed a similar timing about dosing. Kezar remains unaware of which patients received zetomipzomib or the placebo. The FDA has communicated that it will provide Kezar with an official clinical hold letter within 30 days. A severe complication of systemic lupus erythematosus (SLE), LN affects approximately 50% of SLE patients within ten years of diagnosis. The disease is characterised by a range of vascular, glomerular, and tubulointerstitial lesions and is as
Show less
Read more
Impact Snapshot
Event Time:
KZR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KZR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KZR alerts
High impacting Kezar Life Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
KZR
News
- Kezar Life Sciences, Inc. (NASDAQ: KZR) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $11.00. They now have an "equal weight" rating on the stock.MarketBeat
- Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "market perform" rating re-affirmed by analysts at William Blair.MarketBeat
- Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire
- Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)Business Wire
KZR
Earnings
- 11/12/24 - Beat
KZR
Sec Filings
- 11/14/24 - Form 8-K
- 11/14/24 - Form SCHEDULE
- 11/12/24 - Form 10-Q
- KZR's page on the SEC website